AT
The startup develops biomarker-driven targeted therapies that focus on cell cycle regulation, DNA damage response, and previously undruggable cancer targets. This approach enables oncologists to provide more effective treatment options tailored to the specific genetic profiles of tumors, improving patient outcomes in cancer care.
Updated 2 months ago
Funding
$12.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SI
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops biomarker-driven targeted therapies that focus on cell cycle regulation, DNA damage response, and previously undruggable cancer targets. This approach enables oncologists to provide more effective treatment options tailored to the specific genetic profiles of tumors, improving patient outcomes in cancer care.